PCSK9 and non-small cell lung carcinoma: TOP 2201 (NCT05553834) is a phase 2 trial of the PCSK9 inhibitor Alirocumab and the PD-1 inhibitor Cemiplimab in patients with metastatic NSCLC refractory to previous treatment with an anti-PD-1 agent.